{"id":51177,"date":"2026-06-24T11:23:54","date_gmt":"2026-06-24T09:23:54","guid":{"rendered":"https:\/\/semaxpolska.com\/?p=51177"},"modified":"2026-06-21T09:26:38","modified_gmt":"2026-06-21T07:26:38","slug":"pinealona-cilvekiem-petijumi-drosiba-un-fda-statuss","status":"publish","type":"post","link":"https:\/\/bioevidencehub.com\/lv\/pinealon-u-ludzi-badania-bezpieczenstwo-i-status-fda\/","title":{"rendered":"Pinealons cilv\u0113kiem: p\u0113t\u012bjumi, dro\u0161\u012bba un FDA statuss"},"content":{"rendered":"

P\u0113t\u012bjumi ar cilv\u0113kiem par pine\u0101lo dziedzeri<\/h2>\n

Interese par p\u0113t\u012bjumiem ar cilv\u0113kiem par Pinealon ir palielin\u0101jies l\u012bdz ar pieaugo\u0161o interesi par bioregul\u0113jo\u0161iem pept\u012bdiem un intervenc\u0113m, kas atbalsta vesel\u012bgu noveco\u0161anos. Tom\u0113r, izv\u0113rt\u0113jot pieejamos datus, ir svar\u012bgi atz\u012bm\u0113t, ka kl\u012bniskie pier\u0101d\u012bjumi cilv\u0113kiem joproj\u0101m ir ierobe\u017eoti. Lai gan ir public\u0113ti da\u017ei p\u0113t\u012bjumi ar cilv\u0113kiem, pier\u0101d\u012bjumu kopums ir iev\u0113rojami maz\u0101ks nek\u0101 vairumam tradicion\u0101lo farmaceitisko terapiju.<\/p>\n

Viens no galvenajiem cilv\u0113ku p\u0113t\u012bjumiem tika veikts Meshchaninova un kol\u0113\u0123iem, un taj\u0101 piedal\u012bj\u0101s 32 pieaugu\u0161ie vecum\u0101 no 41 l\u012bdz 83 gadiem ar hronisku polimorbidit\u0101ti un rempetantu organisko smadze\u0146u sindromu (1). P\u0113tnieki nov\u0113rt\u0113ja Pinealon un cita bioregul\u0113jo\u0161a pept\u012bda, Vesugen, ietekmi uz biolo\u0123isk\u0101s noveco\u0161an\u0101s biomarkieriem un organisma funkcion\u0101l\u0101 st\u0101vok\u013ca r\u0101d\u012bt\u0101jiem.<\/p>\n

Zin\u0101tnieki atz\u012bm\u0113ja, ka Pinealons izrais\u012bja noz\u012bm\u012bgu anabolisko efektu un tika saist\u012bts ar centr\u0101l\u0101s nervu sist\u0113mas (CNS) aktivit\u0101tes un vair\u0101ku svar\u012bgu org\u0101nu funkciju uzlabo\u0161anos (1). Saska\u0146\u0101 ar p\u0113t\u012bjuma autoriem, \u0161\u012bs izmai\u0146as atbilda biolo\u0123isk\u0101s noveco\u0161an\u0101s r\u0101d\u012bt\u0101ju pal\u0113nin\u0101\u0161anai. P\u0113tnieki secin\u0101ja, ka Pinealons izr\u0101da gan neiroprotekt\u012bvas, gan geroprotekt\u012bvas \u012bpa\u0161\u012bbas, kas var veicin\u0101t vesel\u012bgu noveco\u0161anos un funkcion\u0101l\u0101s sp\u0113jas uztur\u0113\u0161anu gados vec\u0101kiem cilv\u0113kiem.<\/p>\n

P\u0113t\u012bjum\u0101 tika ar\u012b nov\u0113rt\u0113ti vair\u0101ki ar noveco\u0161anos saist\u012bti \u0161\u016bnu un vielmai\u0146as mar\u0137ieri. Lai gan Pinealon par\u0101d\u012bja labv\u0113l\u012bgu ietekmi uz funkcion\u0101lajiem r\u0101d\u012bt\u0101jiem, zin\u0101tnieki atz\u012bm\u0113ja, ka t\u0101 geroprotekt\u012bv\u0101 ietekme \u0161aj\u0101 pa\u0161\u0101 p\u0113t\u012bjum\u0101 (1) \u0161\u0137ita nedaudz maz\u0101k izteikta nek\u0101 Vesugen nov\u0113rot\u0101. Tom\u0113r autori Pinealon atzina par potenci\u0101lu neiroprotekt\u012bvu un geroprotekt\u012bvu pept\u012bdu, kas pelna turpm\u0101ku nov\u0113rt\u0113\u0161anu vec\u0101ka gadag\u0101juma cilv\u0113ku popul\u0101cij\u0101s.<\/p>\n

Neskatoties uz \u0161iem daudzsolo\u0161ajiem atkl\u0101jumiem, j\u0101\u0146em v\u0113r\u0101 vair\u0101ki ierobe\u017eojumi. P\u0113t\u012bjum\u0101 tika iek\u013cauts sal\u012bdzino\u0161i neliels skaits dal\u012bbnieku, tam nebija apjoma, kas parasti nepiecie\u0161ams viennoz\u012bm\u012bgu kl\u012bnisku secin\u0101jumu izdar\u012b\u0161anai, un tas koncentr\u0113j\u0101s uz konkr\u0113tu pacientu grupu (1). Lai apstiprin\u0101tu \u0161os rezult\u0101tus, ir nepiecie\u0161ami turpm\u0101ki p\u0113t\u012bjumi, kas iek\u013cauj liel\u0101kas un daudzveid\u012bg\u0101kas popul\u0101cijas.<\/p>\n

Pa\u0161reiz nav pieejami lielu, vair\u0101kcentru, randomiz\u0113tu, kontrol\u0113tu p\u0113t\u012bjumu, kas nov\u0113rt\u0113tu Pinealon attiec\u012bb\u0101 uz kognit\u012bvo funkciju pasliktin\u0101\u0161anos, Alcheimera slim\u012bbu, vesel\u012bgu noveco\u0161anos vai citiem kl\u012bniskiem lietojumiem. T\u0101pat publiski pieejamu kl\u012bnisko p\u0113t\u012bjumu datub\u0101zu mekl\u0113\u0161ana liecina par sal\u012bdzino\u0161i nelielu re\u0123istr\u0113to cilv\u0113ku p\u0113t\u012bjumu skaitu, sal\u012bdzinot ar s\u012bk\u0101k izp\u0113t\u012btaj\u0101m terapeitiskaj\u0101m viel\u0101m.<\/p>\n

Kopum\u0101 pa\u0161reiz\u0113jie cilv\u0113ku p\u0113t\u012bjumu dati liecina, ka Pinealons var ietekm\u0113t centr\u0101l\u0101s nervu sist\u0113mas darb\u012bbu un ar biolo\u0123isko noveco\u0161anos saist\u012btos biomar\u0137ierus. Tom\u0113r pieejamie kl\u012bniskie dati joproj\u0101m ir s\u0101kotn\u0113ji, un ir nepiecie\u0161ami turpm\u0101ki, labi izstr\u0101d\u0101ti kl\u012bniskie p\u0113t\u012bjumi, pirms var izdar\u012bt gal\u012bgus secin\u0101jumus par t\u0101 efektivit\u0101ti, dro\u0161umu un terapeitisko potenci\u0101lu cilv\u0113kiem.<\/p>\n

Dro\u0161\u012bba un blakuspar\u0101d\u012bbas Pinealon<\/h2>\n

Pa\u0161laik pieejamie dati liecina, ka Pinealon parasti tiek labi panesams gan eksperiment\u0101los dz\u012bvnieku p\u0113t\u012bjumos, gan ierobe\u017eot\u0101 skait\u0101 l\u012bdz \u0161im veikto cilv\u0113ku p\u0113t\u012bjumu. Tom\u0113r, t\u0101 k\u0101 kl\u012bniskie dati par cilv\u0113kiem joproj\u0101m ir sam\u0113r\u0101 reti, t\u0101 kop\u0113jais dro\u0161\u012bbas profils v\u0113l nav piln\u012bb\u0101 raksturots, \u012bpa\u0161i attiec\u012bb\u0101 uz ilgsto\u0161u lieto\u0161anu.<\/p>\n

V\u0113rt\u012bg\u0101kie dro\u0161\u012bbas dati n\u0101k no Meshchaninova un kol\u0113\u0123u veikt\u0101 p\u0113t\u012bjuma, kur\u0101 piedal\u012bj\u0101s 32 pieaugu\u0161ie vecum\u0101 no 41 l\u012bdz 83 gadiem ar hronisku polimorbidit\u0101ti un remisij\u0101 eso\u0161u organisku smadze\u0146u sindromu (1). P\u0113tnieki nov\u0113roja centr\u0101l\u0101s nervu sist\u0113mas darb\u012bbas un biolo\u0123isk\u0101s noveco\u0161an\u0101s biomarkeru uzlabo\u0161anos, nepiesakot b\u016btiskas ar dro\u0161\u012bbu saist\u012btas probl\u0113mas p\u0113t\u012bjuma period\u0101. Svar\u012bgi, ka Pinealon ne\u0161\u0137ita negat\u012bvi ietekm\u0113jot hromant\u012bna kondens\u0101ciju, liekot autoriem secin\u0101t, ka pept\u012bds uzr\u0101da dro\u0161\u012bbu \u0161\u016bnu kodola \u0123en\u0113tisk\u0101 stabilit\u0101tes l\u012bmen\u012b p\u0113t\u012btajos apst\u0101k\u013cos (1).<\/p>\n

P\u0113t\u012bjumi ar dz\u012bvniekiem un \u0161\u016bn\u0101m ar\u012b nor\u0101da uz labv\u0113l\u012bgu dro\u0161\u012bbas profilu. P\u0113t\u012bjumi, kuros tika nov\u0113rt\u0113ta Pinealon ietekme uz oksidat\u012bvo stresu, neironu dz\u012bvotsp\u0113ju un kognit\u012bv\u0101s funkcijas, parasti par\u0101d\u012bja aizsarg\u0101jo\u0161u, nevis kait\u012bgu ietekmi (2\u20134). Eksperiment\u0101los mode\u013cos Pinealon samazin\u0101ja oksidat\u012bvos boj\u0101jumus, ierobe\u017eoja reakt\u012bvo sk\u0101bek\u013ca savienojumu uzkr\u0101\u0161anos, uzlaboja neironu dz\u012bvotsp\u0113ju un samazin\u0101ja \u0161\u016bnu nekrozi, bez iev\u0113rojamas toksicit\u0101tes paz\u012bm\u0113m nov\u0113rt\u0113taj\u0101s dev\u0101s (2,3).<\/p>\n

Neskatoties uz daudzsolo\u0161ajiem rezult\u0101tiem, j\u0101\u0146em v\u0113r\u0101 vair\u0101ki b\u016btiski ierobe\u017eojumi. Cilv\u0113ku p\u0113t\u012bjumi joproj\u0101m ir ierobe\u017eoti dal\u012bbnieku skaita un ilguma zi\u0146\u0101, padarot gr\u016bti identific\u0113t retas nev\u0113lamas blakuspar\u0101d\u012bbas un piln\u012bb\u0101 nov\u0113rt\u0113jot ilgtermi\u0146a dro\u0161umu. Turkl\u0101t v\u0113l nav veikti lieli, nejau\u0161in\u0101ti, kontrol\u0113ti p\u0113t\u012bjumi, kas \u012bpa\u0161i izstr\u0101d\u0101ti dro\u0161uma nov\u0113rt\u0113\u0161anai.<\/p>\n

T\u0101d\u0113j\u0101di Pinealon ilgtermi\u0146a dro\u0161\u012bbas profils joproj\u0101m ir neskaidrs. Jaut\u0101jumi, kas saist\u012bti ar hronisku lieto\u0161anu, atk\u0101rtotiem \u0101rst\u0113\u0161anas cikliem, iesp\u0113jam\u0101m z\u0101\u013cu mijiedarb\u012bb\u0101m un lieto\u0161anu noteikt\u0101s popul\u0101cij\u0101s, nav pien\u0101c\u012bgi izp\u0113t\u012bti lielos kl\u012bniskos p\u0113t\u012bjumos. Person\u0101m ar eso\u0161\u0101m vesel\u012bbas probl\u0113m\u0101m pirms jebk\u0101da eksperiment\u0101la pept\u012bda lieto\u0161anas ir j\u0101konsult\u0113jas ar kvalific\u0113tu vesel\u012bbas apr\u016bpes speci\u0101listu.<\/p>\n

Pamatojoties uz pa\u0161laik pieejamajiem datiem, Pinealon \u0161\u0137iet labi panesams p\u0113t\u012bjumu apst\u0101k\u013cos, un public\u0113tajos p\u0113t\u012bjumos nav identific\u0113ti nek\u0101di noz\u012bm\u012bgi dro\u0161\u012bbas sign\u0101li. Tom\u0113r cilv\u0113ku izp\u0113tes ierobe\u017eotais apjoms noz\u012bm\u0113, ka pirms visaptvero\u0161u secin\u0101jumu par dro\u0161umu izdar\u012b\u0161anas ir nepiecie\u0161ami papildu kl\u012bniskie p\u0113t\u012bjumi.<\/p>\n

Pinealon apstiprin\u0101\u0161ana ar FDA un t\u0101 regulat\u012bvais statuss<\/h2>\n

Daudzi cilv\u0113ki, kuri mekl\u0113 inform\u0101ciju par Pinealon, v\u0113las noskaidrot, vai to ir apstiprin\u0101jusi Amerikas Savienoto Valstu P\u0101rtikas un z\u0101\u013cu p\u0101rvalde (FDA) un vai tas ir atz\u012bts par apstiprin\u0101t\u0101m z\u0101l\u0113m Amerikas Savienotaj\u0101s Valst\u012bs. Pamatojoties uz pa\u0161laik pieejamo regulat\u012bvo inform\u0101ciju, Pinealon nav apstiprin\u0101jusi FDA, lai \u0101rst\u0113tu, nov\u0113rstu vai diagnostic\u0113tu jebkuru slim\u012bbu.<\/p>\n

Mekl\u0113\u0161ana publiski pieejam\u0101s FDA z\u0101\u013cu datub\u0101z\u0113s neliecina, ka Pinealon ir apstiprin\u0101tas recep\u0161u z\u0101les. T\u0101pat Pinealon nav atrodams Drugs@FDA datub\u0101z\u0113 k\u0101 apstiprin\u0101ts terapeitisks produkts. Tas noz\u012bm\u0113, ka Pinealon nav izg\u0101jis pla\u0161o normat\u012bvo nov\u0113rt\u0113\u0161anas procesu, kas nepiecie\u0161ams, lai ieg\u016btu farmaceitisko apstiprin\u0101jumu Amerikas Savienotaj\u0101s Valst\u012bs.<\/p>\n

T\u0101 viet\u0101 Pinealon parasti tiek uzskat\u012bts par eksperiment\u0101lu biore\u0123ener\u0113jo\u0161u pept\u012bdu vai p\u0113tniec\u012bbas pept\u012bdu. Liel\u0101k\u0101 da\u013ca pa\u0161laik pieejamo zin\u0101tnisko pier\u0101d\u012bjumu n\u0101k no laboratorijas p\u0113t\u012bjumiem, dz\u012bvnieku p\u0113t\u012bjumiem un ierobe\u017eota skaita cilv\u0113ku p\u0113t\u012bjumu, kas galvenok\u0101rt veikti Krievij\u0101 un Austrumeirop\u0101 (1\u20134). Lai gan \u0161ie p\u0113t\u012bjumi ir par\u0101d\u012bju\u0161i potenci\u0101li labv\u0113l\u012bgu biolo\u0123isko ietekmi, tie nav pietiekami, lai attaisnotu FDA apstiprin\u0101jumu vai noteiktu atz\u012btas medic\u012bnisk\u0101s indik\u0101cijas.<\/p>\n

FDA neapstiprin\u0101\u0161ana nenoz\u012bm\u0113 autom\u0101tiski, ka savienojumam nav biolo\u0123iskas aktivit\u0101tes. T\u0101 noz\u012bm\u0113, ka FDA regul\u0101cijas procesa ietvaros nav iesniegti un apstiprin\u0101ti pietiekami pier\u0101d\u012bjumi par dro\u0161umu, efektivit\u0101ti, ra\u017eo\u0161anas kvalit\u0101ti un kl\u012bniskajiem ieguvumiem.<\/p>\n

P\u0113tnieki joproj\u0101m analiz\u0113 Pinealonu attiec\u012bb\u0101 uz iesp\u0113jamu pielietojumu neiroprotekcijas, kognit\u012bvo funkciju, oksidat\u012bv\u0101 stresa regul\u0113\u0161anas un vesel\u012bgas noveco\u0161anas jom\u0101s. Tom\u0113r \u0161\u012bs jomas joproj\u0101m ir eksperiment\u0101las, un pa\u0161laik neviens galvenais regulat\u012bvais dienests nav atzinis Pinealonu k\u0101 apstiprin\u0101tu terapiju neirolo\u0123iskiem trauc\u0113jumiem, ar vecumu saist\u012bt\u0101m slim\u012bb\u0101m vai jebk\u0101dai citai medic\u012bniskai indik\u0101cijai.<\/p>\n

T\u0101d\u0113\u013c Pinealon pa\u0161laik j\u0101uzskata par p\u0113tniec\u012bbas vielu, nevis apstiprin\u0101tu farmaceitisko produktu. Person\u0101m, kuras interes\u0113jas par Pinealon, j\u0101apzin\u0101s, ka apgalvojumi par t\u0101 terapeitisko iedarb\u012bbu galvenok\u0101rt balst\u012bti uz prekl\u012bniskiem datiem un ierobe\u017eotu skaitu cilv\u0113ku p\u0113t\u012bjumu, nevis uz atz\u012btu regulatoru apstiprin\u0101jumu.<\/p>\n

Atruna<\/h3>\n

Saturs ir paredz\u0113ts tikai izgl\u012btojo\u0161iem un informat\u012bviem nol\u016bkiem, un to nedr\u012bkst interpret\u0113t k\u0101 medic\u012bnisku padomu, diagnozi, \u0101rst\u0113\u0161anu vai profesion\u0101lu ieteikumu. Pinealon nav apstiprin\u0101jusi Amerikas P\u0101rtikas un z\u0101\u013cu p\u0101rvalde (FDA), Eiropas Z\u0101\u013cu a\u0123ent\u016bra (EMA) vai liel\u0101k\u0101 da\u013ca citu regul\u0113jo\u0161o iest\u0101\u017eu, lai \u0101rst\u0113tu kognit\u012bvo sp\u0113ju pasliktin\u0101\u0161anos, neirolo\u0123iskus trauc\u0113jumus, ar noveco\u0161anos saist\u012btus st\u0101vok\u013cus vai jebk\u0101dus citus medic\u012bniskus indik\u0101cijas. Liel\u0101k\u0101 da\u013ca pieejamo datu n\u0101k no prekl\u012bniskiem p\u0113t\u012bjumiem un ierobe\u017eota skaita cilv\u0113ku p\u0113t\u012bjumiem, no kuriem daudzos tika iek\u013cautas nelielas p\u0113t\u012bjumu dal\u012bbnieku grupas. Nepiecie\u0161ami turpm\u0101ki, labi izstr\u0101d\u0101ti kl\u012bniskie p\u0113t\u012bjumi, lai lab\u0101k noteiktu Pinealon efektivit\u0101ti, dro\u0161umu, ilgtermi\u0146a ietekmi un potenci\u0101los terapeitiskos lietojumus da\u017e\u0101d\u0101s popul\u0101cij\u0101s.<\/p>\n

Atsauces<\/h4>\n

(1)<\/strong> Me\u0161\u010daninovs, V. N., Tka\u010denko, E. L., \u017darkovs, S. V., Gavrilovs, I. V., & Katireva, J. E. (2015). Sint\u0113tisko pept\u012bdu ietekme uz pacientu ar hronisku polimorbidit\u0101ti un centr\u0101l\u0101s nervu sist\u0113mas organisko smadze\u0146u sindromu remonta laik\u0101 noveco\u0161anos<\/em>. Gerontolo\u0123ijas sasniegumi, 28<\/em>(1), 62\u201367.<\/span>
PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\/26390612\/<\/a><\/span><\/p>\n

(2)<\/strong> Arutjunjan, A. V., Kozina, L. S., Stvolinsky, S. L., Bulygina, E. R., Ma\u0161kina, A. P., & Havinsona, V. K. (2012). Pinealons pasarg\u0101 \u017eurku p\u0113cn\u0101c\u0113jus no pirmsdzemd\u012bbu hiperhomocistein\u0113mijas<\/em>. International Journal of Peptides, 2012<\/em>, 109757. https:\/\/doi.org\/10.1155\/2012\/109757<\/a><\/span>
PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\/22567179\/<\/a><\/span>
PMC pilns teksts: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3342713\/<\/a><\/span><\/p>\n

(3)<\/strong> Khavinson, V., Ribakova, Y., Trofimova, S. un citi. (2011). Pinealon palielina \u0161\u016bnu dz\u012bvotsp\u0113ju, nom\u0101cot br\u012bvo radik\u0101\u013cu l\u012bmeni un aktiviz\u0113jot proliferat\u012bvus procesus<\/em>. Atjauno\u0161an\u0101s p\u0113t\u012bjumu, 14<\/em>(5), 517\u2013523. https:\/\/doi.org\/10.1089\/rej.2011.1172<\/a><\/span>
\u017durn\u0101la saite: https:\/\/journals.sagepub.com\/doi\/abs\/10.1089\/rej.2011.1172<\/a><\/span><\/p>\n

(4)<\/strong> Khavinsona, V., I\u013cina, A., Kraskovska, N., Linkova, N., Kol\u010dina, N., Mironova, E., Jerofejevs, A., & Petuhovs, M. (2021). Neiroprotekt\u012bv\u0101 ietekme tripept\u012bdiem \u2014 epigen\u0113tiskiem regulatoriem Alcheimera slim\u012bbas peles model\u012b<\/em>. Farmaceitikas, 14<\/em>(6), 515. https:\/\/doi.org\/10.3390\/ph14060515<\/a><\/span>
\u017durn\u0101la saite: https:\/\/www.mdpi.com\/1424-8247\/14\/6\/515<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"

P\u0113t\u012bjumi ar cilv\u0113kiem par Pinealonu. Interese par p\u0113t\u012bjumiem ar cilv\u0113kiem par Pinealonu ir pieaugusi l\u012bdz ar augo\u0161o interesi par bioregul\u0113jo\u0161iem pept\u012bdiem un intervenc\u0113m, kas veicina vesel\u012bgu noveco\u0161anu. V\u0113rt\u0113jot\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[253],"tags":[],"class_list":["post-51177","post","type-post","status-publish","format-standard","hentry","category-kategoria-pinealon","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/51177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=51177"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/51177\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=51177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=51177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=51177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}